Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Administration of 2 -Adrenergic Agonists During the Peri-Implantation Period Does Not Improve Implantation or Pregnancy Rates in Intracytoplasmic Sperm Injection (ICSI) Cycles

2003; Springer Science+Business Media; Volume: 20; Issue: 12 Linguagem: Inglês

10.1023/b

1573-7330

Osni L. Pinheiro, Mário Cavagna, Ricardo Luiz Razera Baruffi, Ana L. Mauri, Cláudia G. Petersen, José G. Franco,

Assisted Reproductive Technology and Twin Pregnancy

Purpose : The objective of the present investigation was to determine implantation and pregnancy rates in patients undergoing ICSI and treated with β 2-adrenergic agonists, considering the uterine-relaxing action of these agents. Methods : A total of 225 women undergoing ICSI at the Center for Human Reproduction, “Sinhá Junqueira” Maternity Foundation, entered the study. Patient participation in each group was random, by drawing lots, using a randomization table previously elaborated for the study (2:2:1). The group I (90 women) received 10 mg of terbutaline daily for 15 days starting on the day of oocyte retrieval; group II (90 women) received 20 mg of ritodrine daily during the same period of time as group I; group III (45 patients) received no treatment and was used as control. The evaluation was interrupted in 3 patients of group I and in 30 patients of group II because of a high incidence of side effects. Results : Pregnancy, implantation, and miscarriage rates were not significantly different (p > 0.05) between the three groups: 29.88%, 13.25%, and 26.9% for group I; 33.33%, 17.5%, and 10.0% for group II; 28.88%, 15.07%, and 15.38% for group III, respectively. Conclusions : The results of this study do not support the routine use of β 2-adrenergic agonists during the peri-implantation period in assisted reproductive technology cycles.